Orsolini, Laura

Novel psychoactive substances of interest for psychiatry

Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry

Forensic Toxicology and Drug AnalysisPsychedelics and Drug Studies

Cited by 321

C-Reactive protein as a biomarker for major depressive disorder?

Orsolini, L., Pompili, S., Tempia Valenta, S., Salvi, V., & Volpe, U. (2022) · International Journal of Molecular Sciences

Tryptophan and brain disordersTreatment of Major Depression

Cited by 171

An update of safety of clinically used atypical antipsychotics

Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., Iasevoli, F., Buonaguro, E. F., Fornaro, M., Fiengo, A. L. C., et al. (2016) · Expert Opinion on Drug Safety

Schizophrenia research and treatmentBipolar Disorder and Treatment

Cited by 135

The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review

Orsolini, L., Papanti, G. D., De Berardis, D., Guirguis, A., Corkery, J. M., & Schifano, F. (2017) · Frontiers in Psychiatry

Psychedelics and Drug StudiesHallucinations in medical conditions

Cited by 99

Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces

Orsolini, L., Francesconi, G., Papanti, D., Giorgetti, A., & Schifano, F. (2015) · Human Psychopharmacology Clinical and Experimental

Cybercrime and Law Enforcement StudiesPharmaceutical Quality and Counterfeiting

Cited by 70

COVID-19-Related Social Isolation Predispose to Problematic Internet and Online Video Gaming Use in Italy

Volpe, U., Orsolini, L., Salvi, V., Albert, U., Carmassi, C., Carrà, G., Cirulli, F., Dell’Osso, B., Luciano, M., Menculini, G., et al. (2022) · International Journal of Environmental Research and Public Health

Impact of Technology on AdolescentsCOVID-19 and Mental Health

Cited by 57

Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System

Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., Carano, A., Pompili, M., Serafini, G., Perna, G., et al. (2019) · Current Pharmaceutical Design

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 44

Public health approaches and policy changes after the inclusion of gaming disorder in ICD-11: global needs

Long, J., Bhad, R., Potenza, M. N., Orsolini, L., Phan, V., Kanabar, M., & Achab, S. (2022) · BJPsych International

Impact of Technology on AdolescentsGambling Behavior and Treatments

Cited by 35

Evolutionary Considerations on the Emerging Subculture of the E-psychonauts and the Novel Psychoactive Substances: A Comeback to the Shamanism?

Orsolini, L., St John-Smith, P., McQueen, D., Papanti, D., Corkery, J., & Schifano, F. (2017) · Current Neuropharmacology

Psychedelics and Drug StudiesForensic Toxicology and Drug Analysis

Cited by 28

The consequences of drug misuse on post-marketing surveillance

Schifano, F., Papanti, G. D., Orsolini, L., & Corkery, J. M. (2016) · Expert Review of Clinical Pharmacology

Pharmacovigilance and Adverse Drug ReactionsForensic Toxicology and Drug Analysis

Cited by 21